ARTICLE | Clinical News

Hansa reports Phase II data of IdeS in kidney transplant patients

March 2, 2018 6:39 PM UTC

Hansa Medical AB (SSE:HMED) reported interim data from 18 highly sensitized patients awaiting a kidney transplant with a positive crossmatch test prior to receiving IdeS in the Phase II Highdes trial showing that IdeS treatment converted the positive crossmatch to negative in all patients. All 18 patients have subsequently received a kidney transplant and will be followed for six months.

In seven evaluable patients who subsequently received a kidney transplant, three experienced antibody mediated rejection that responded to standard of care (SOC) and three had delayed graft function that ultimately resolved. All seven patients had functioning kidneys at a median follow-up of 5.5 months. Data will be presented at the American Surgical Association meeting in Phoenix in April, with final data from all 18 patients expected by 3Q18...

BCIQ Company Profiles

Hansa Biopharma AB

BCIQ Target Profiles

Immunoglobulin G (IgG)